Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China

• Main Authors: Zhiqiang Wang (Author), Zhibo Zhang (Author), Yong Li (Author), Li Sun (Author), Dezhen Peng (Author), Danyu Du (Author), Xian Zhang (Author), Luwei Han (Author), Liwen Zhao (Author), Ligong Lu (Author), Hongzhi Du (Author), Shengtao Yuan (Author), Meixiao Zhan (Author)
• Format: Book
• Published: Elsevier, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Acute myeloid leukaemia (AML) is the most common form of acute leukaemia in adults, with increasing incidence with age and a generally poor prognosis. Almost 20% of AML patients express mutant isocitrate dehydrogenase 2 (mIDH2), which leads to the accumulation of the carcinogenic metabolite 2-hydrox...